Expertise in
2
conditions

Dr. Evangelia D. Razis

Oncology
Office
362 Kifissias Ave, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Office
362 Kifissias Ave, 
Pittsburgh, PA 

Overview

Evangelia Razis is an Oncologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Razis is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, and Brain Tumor.

She is actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
362 Kifissias Ave, Pittsburgh, PA 15233

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)
Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)
Enrollment Status: Terminated
Publish Date: November 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Enrollment Status: Completed
Publish Date: August 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

91 Total Publications

Clear Cell Carcinoma of the Abdominal Wall: An Aggressive Endometriosis-Associated Malignant Disease.
Clear Cell Carcinoma of the Abdominal Wall: An Aggressive Endometriosis-Associated Malignant Disease.
Journal: Cureus
Published: July 04, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (1.7 miles away)
412-359-6391
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nathan Bahary is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Bahary is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

UPMC Presbyterian

200 Lothrop St, 
Pittsburgh, PA 
 (4.1 miles away)
412-383-1370
Languages Spoken:
English
See accepted insurances

Jason Luke is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Luke is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Office

5150 Centre Ave, 
Pittsburgh, PA 
 (4.9 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is an Oncologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Appleman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Frequently Asked Questions about Dr. Evangelia D. Razis

How do I make an appointment with Dr. Evangelia D. Razis?

You can book an appointment with Dr. Evangelia D. Razis by calling their office at 693-240-5390. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Evangelia D. Razis a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Evangelia D. Razis is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Evangelia D. Razis specialize in?

While Dr. Evangelia D. Razis is a Oncology, they have specific expertise in Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Triple-Negative Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Evangelia D. Razis participate in research or clinical trials?

Yes. Dr. Evangelia D. Razis has published 91 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Evangelia D. Razis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Razis's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile